Systems genetics for drug target discovery

被引:29
|
作者
Penrod, Nadia M. [1 ]
Cowper-Sal-Iari, Richard [1 ]
Moore, Jason H. [1 ,2 ]
机构
[1] Dartmouth Med Sch, Computat Genet Lab, Lebanon, NH 03756 USA
[2] Dartmouth Med Sch, Inst Quantitat Biomed Sci, Lebanon, NH 03756 USA
关键词
CHRONIC MYELOGENOUS LEUKEMIA; GENOME-WIDE ASSOCIATION; FACTOR-H POLYMORPHISM; TYROSINE KINASE; MISSING HERITABILITY; ABL PROTEIN; EXPRESSION; IDENTIFICATION; COMPLEMENT; CELLS;
D O I
10.1016/j.tips.2011.07.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The collection and analysis of genomic data has the potential to reveal novel druggable targets by providing insight into the genetic basis of disease. However, the number of drugs targeting new molecular entities, approved by the US Food and Drug Administration has not increased in the years since the collection of genomic data has become commonplace. The paucity of translatable results can be partly attributed to conventional analysis methods that test one gene at a time in an effort to identify disease-associated factors as candidate drug targets. By disengaging genetic factors from their position within the genetic regulatory system, much of the information stored within the genomic data set is lost. Here we discuss how genomic data is used to identify disease-associated genes or genomic regions, how disease-associated regions are validated as functional targets, and the role network analysis can play in bridging the gap between data generation and effective drug target identification.
引用
收藏
页码:623 / 630
页数:8
相关论文
共 50 条
  • [21] Neuropeptide signalling systems - An underexplored target for venom drug discovery
    Mendel, Helen C.
    Kaas, Quentin
    Muttenthaler, Markus
    [J]. BIOCHEMICAL PHARMACOLOGY, 2020, 181
  • [22] From drug to protein: using yeast genetics for high-throughput target discovery
    Armour, CD
    Lum, PY
    [J]. CURRENT OPINION IN CHEMICAL BIOLOGY, 2005, 9 (01) : 20 - 24
  • [23] Full-speed mammalian genetics:: in vivo target validation in the drug discovery process
    Abuin, A
    Holt, KH
    Platt, KA
    Sands, AT
    Zambrowicz, BP
    [J]. TRENDS IN BIOTECHNOLOGY, 2002, 20 (01) : 36 - 42
  • [24] Genetics of complex disorders and drug discovery
    Middleton, L
    [J]. JOURNAL OF MEDICAL GENETICS, 2003, 40 : S13 - S13
  • [25] Cancer genetics and drug discovery in the zebrafish
    Howard M. Stern
    Leonard I. Zon
    [J]. Nature Reviews Cancer, 2003, 3 : 533 - 539
  • [26] Target class drug discovery
    Kimberly D Barnash
    Lindsey I James
    Stephen V Frye
    [J]. Nature Chemical Biology, 2017, 13 : 1053 - 1056
  • [27] Target discovery using biobanks and human genetics
    Hicks, Michael A.
    Hou, Claire Y. C.
    Iranmehr, Arya
    Marosi, Krisztina
    Kirkness, Ewen
    [J]. DRUG DISCOVERY TODAY, 2020, 25 (02) : 438 - 445
  • [28] Proteomics for drug target discovery
    Gottfries, J
    Sjögren, M
    Holmberg, B
    Rosengren, L
    Davidsson, P
    Blennow, K
    [J]. CHEMOMETRICS AND INTELLIGENT LABORATORY SYSTEMS, 2004, 73 (01) : 47 - 53
  • [29] The adipocyte as a drug discovery target
    Nawrocki, AR
    Scherer, PE
    [J]. DRUG DISCOVERY TODAY, 2005, 10 (18) : 1219 - 1230
  • [30] Genomics in target and drug discovery
    van Duin, M
    Woolson, H
    Mallinson, D
    Black, D
    [J]. BIOCHEMICAL SOCIETY TRANSACTIONS, 2003, 31 : 429 - 432